Updates on Botulinum Neurotoxins in Dermatology

Hanna, Edith; Pon, Kucy

doi:10.1007/s40257-019-00482-2

Cited by 22 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A major difficulty in the interpretation of studies using BtA is the presence of a large number of different commercially available preparations (e.g., onabotulinumtoxin A, abobotulinumtoxin A, incobotulinumtoxin A, etc.). [ 12 ] One unit of a given preparation is specific and is not comparable to one unit of any other preparation because of the differences in the vehicle dilution schemes, the laboratory protocols, and the differences in species sensitivities. [ 13 ] Therefore, the results of any study can only reflect the specific variant of BtA that is used and cannot be extrapolated to all the different preparations available in the market.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study

Chakrabarty

Maneksha

Tanwar

et al. 2021

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: The aim of this study was to report the outcomes of a regional variant of botulinum toxin type A (BtA) in essential blepharospasm and hemifacial spasm. Methods: The medical records of all patients with facial dystonias, who received at least one dose of BtA between May 2016 and April 2017 were retrospectively evaluated. The pre- and post-injection severity of symptoms, graded using the Jankovic rating system for essential blepharospasm and the Samsung Medical Center grading system for hemifacial spasm, the complications after each sitting, and the mean symptom-free interval were recorded. A correlation analysis was done to identify factors associated with longer symptom-free intervals. A P value < 0.05 was considered statistically significant. Results: The mean age at presentation was 56.62 ± 10.56 years. The mean duration of follow-up was 1.86 ± 2.06 years. The modal disease severity reduced from 5 to 0 in essential blepharospasm and from 2 to 0 in hemifacial spasm a week after injection of botulinum toxin. The mean symptom-free intervals with doses of 20, 22.5, 25, 30, and 50 units were 102.1 ± 44.7, 132.4 ± 35.3, 147.2 ± 61.6, 124.4 ± 55.1, and 142.4 ± 59.7 days, respectively. The commonest complication was lagophthalmos (26.3%; n = 20). Injections for primary dystonias were associated with longer disease-free intervals than those for secondary dystonias ( P = 0.02). In nine sittings, the dose was increased for increased severity or presumed resistance, which resulted in a significant increase in the symptom-free interval ( P = 0.004) without an increased incidence of complications ( P = 0.48). Conclusion: BtA is safe and effective in the treatment of facial dystonias. The drug is more efficacious for primary facial dystonias.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study

Chakrabarty

Maneksha

Tanwar

et al. 2021

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…DaxiBoNT-A is a novel BoNT with a stabilizing peptide to promote longer-lasting effects. It has no animal-derived components or human albumin, similar to IncoBoNT-A, and does not require refrigeration with a shelf-life of two years [52]. This toxin was shown to have a mean response duration of 25 weeks in CD in a phase II study [53], and a phase III multicenter study of its use in CD is currently underway [54].…”

Section: Other Toxins Not Fda-approved For Dystoniamentioning

confidence: 99%

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia

Spiegel

Ostrem

Bledsoe

2020

Toxins

View full text Add to dashboard Cite

In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Several BoNT formulations have been introduced to the market since then. 2 BoNTs have been used for spasticity, depression, hyperhidrosis, migraines, and aging of the neck, face, and decolletage on and off label in the medical and cosmetic areas since their commercial availability. 3,4 C. botulinum secretes a three-protein complex that includes a 150 kDa toxin, a nontoxic, non-haemagglutinin protein, and a non-toxic haemagglutinin protein.…”

Section: Introductionmentioning

confidence: 99%

“…Toxin light chains cleave vesicle-associated membrane protein/ synaptobrevin (BoNT-B, D, F, G) or synaptosomal-associated protein 25 (BoNT-A, C, E), preventing acetylcholine release from peripheral motor neuron axons and resulting in transient chemical denervation and muscle paralysis. 2 In the United States, there are four commercially available, FDA-approved BoNT-A formulations: incobotulinumtoxinA (Frankfurt, Germany), onabotulinumtoxinA (California, USA), prabotulinumtoxinA-xvfs (California, USA) and abobotulinumtoxinA (Arizona, USA); as well as one BoNT-B: rimabotulinumtoxinB (California, USA). 5 A review by Guida et al 6 evaluated the role of BoNT in the field of dermatology.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Utilities of Botulinum Toxins in Dermatology and Cosmetology

Naik¹

2021

CCID

View full text Add to dashboard Cite

Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacterium with a well-known efficacy and safety profile in the focal idiopathic hyperhidrosis treatment. BoNT comprises seven different neurotoxins; however, only toxins A and B are clinically employed. BoNT is lately practiced in off-label therapies for a variety of skin diseases. Scar prevention, hyperhidrosis, rhytides, eccrine nevus, alopecia, psoriasis, Darier disease, bullous skin disease, pompholyx and Raynaud’s phenomenon are some of the novel indications for BoNT in cosmetic and notably non-cosmetic aspects of dermatology. To employ BoNT correctly in clinical practice, we must have a thorough understanding of the functional anatomy of the mimetic muscles. An intensive literature search was conducted to update all dermatology-oriented experiments and clinical trials on the described element of BoNT for this general overview of BoNT use in dermatology. This review aims to analyse the role of BoNT in dermatology and cosmetology.

show abstract

Updates on Botulinum Neurotoxins in Dermatology

Cited by 22 publications

References 12 publications

Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study

Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia

Utilities of Botulinum Toxins in Dermatology and Cosmetology

Contact Info

Product

Resources

About